ISPOR Asia Pacific Summit 2026
6-8 September
-
MODELLING THE COST-EFFECTIVENESS OF INTERVENTIONS FOR INDIVIDUALS WITH MULTIMORBIDITY IN NEW ZEALAND: A DISCRETE EVENT SIMULATION...
Jul 9, 2026, 19:54 PM -
VALUE FRAMEWORK AND METHOD OF EARLY HEALTH TECHNOLOGY ASSESSMENT: A SCOPING REVIEW
Jul 9, 2026, 19:54 PM -
BRIDGING THE POLICY GAP IN MULTIPLE MYELOMA TREATMENT: A CASE STUDY USING A HORIZON SCANNING OF TREATMENT OPTIONS FOR TRANSPLANT-INELIGIBLE PATIENTS IN THAILAND
Jul 9, 2026, 19:54 PM -
COST-EFFECTIVENESS OF BLINATUMOMAB FOR PEDIATRIC HIGH-RISK RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN BRAZIL: A REAL-WORLD ECONOMIC EVALUATION
Jul 9, 2026, 19:54 PM -
ECONOMIC EVALUATION OF NT-PROBNP-SUPPORTED INTENSIVE POST-DISCHARGE HEART FAILURE CARE IN VIETNAM
Jul 9, 2026, 19:54 PM -
UNDERSTANDING MULTIMORBIDITY AS A DRIVER OF HIGH-COST STATUS IN DIABETES: EVIDENCE FROM LONGITUDINAL CLAIMS DATA IN CHINA
Jul 9, 2026, 19:54 PM -
WHEN DOES MESSAGE FRAMING MATTER? DISEASE CONTEXT AND PSYCHOLOGICAL MODERATORS OF CANCER SCREENING PREFERENCES IN URBAN CHINA
Jul 9, 2026, 19:54 PM -
POPULATION-LEVEL OUTPATIENT HEALTHCARE COSTS ATTRIBUTABLE TO DISEASES: A LONGITUDINAL REGRESSION ANALYSIS OF A JAPANESE INSURER-BASED CLAIMS DATABASE
Jul 9, 2026, 19:54 PM -
ASSOCIATION OF CISPLATIN INDUCED NEPHROTOXICITY AND OTOTOXICITY WITH HEALTH-RELATED QUALITY OF LIFE AND ECONOMIC BURDEN IN CANCER PATIENTS
Jul 9, 2026, 19:54 PM -
MEDICAL EXPENDITURES DECREASED FOLLOWING POLICY INTERVENTIONS TO ACCELERATE BIOSIMILAR UTILIZATION IN JAPAN: A NATIONWIDE SERIAL CROSS-SECTIONAL ANALYSIS
Jul 9, 2026, 19:54 PM -
DIAGNOSTIC ACCURACY OF DIGITAL HEMOGLOBINOMETERS: EVIDENCE SYNTHESIS AND RECOMMENDATIONS
Jul 9, 2026, 19:54 PM -
LUNG CANCER SCREENING IN THE ASIA PACIFIC REGION: A SCOPING REVIEW OF CURRENT SCREENING POLICY GUIDELINES AND BEST PRACTICES
Jul 9, 2026, 19:54 PM -
EVALUATING THE IMPLEMENTATION AND IMPACT OF INDONESIA’S NATIONAL HEALTH SERVICE TARIFF STANDARD ON PROVIDER PAYMENT EFFICIENCY AND FINANCIAL SUSTAINABILITY
Jul 9, 2026, 19:54 PM -
INDIRECT TREATMENT COMPARISON OF MARSTACIMAB VERSUS FITUSIRAN ANTITHROMBIN-BASED DOSE REGIMEN AMONG INDIVIDUALS WITH HEMOPHILIA A/B, WITHOUT INHIBITORS, WHO PREVIOUSLY RECEIVED ON-DEMAND THERAPY
Jul 9, 2026, 19:54 PM -
AI CHATBOT-ENABLED PATIENT GROUP MANAGEMENT IN RARE DISEASES: OUTCOMES FROM A REAL-WORLD WECHAT-BASED DEPLOYMENT IN CHINA
Jul 9, 2026, 19:54 PM -
SOCIETAL VALUE OF INNOVATIVE THERAPIES: EVIDENCE FROM HER2-TARGETED THERAPIES IN CHINA...
Jul 9, 2026, 19:54 PM -
PATIENT INVOLVEMENT IN RARE DISEASE HEALTH TECHNOLOGY ASSESSMENT (HTA): REAL-WORLD PRACTICES IN AUSTRALIA, SINGAPORE, AND TAIWAN
Jul 9, 2026, 19:54 PM -
HOW DO COUNTRIES JUSTIFY INVESTMENT IN GENOMICS RESEARCH INFRASTRUCTURE? LESSONS FOR HEALTH ECONOMIC EVALUATION
Jul 9, 2026, 19:54 PM -
MATERNAL ADVERSE CHILDHOOD EXPERIENCES AND OFFSPRING HEALTH-RELATED QUALITY OF LIFE: THE MEDIATING ROLES OF FAMILY HARMONY AND PARENTING STYLES...
Jul 9, 2026, 19:54 PM -
HEALTH ECONOMIC EVALUATION MODEL FOR BREAST CANCER RISK MANAGEMENT THROUGH PREIMPLANTATION GENETIC TESTING FOR MONOGENIC DISORDERS (PGT-M) IN BRCA1/2 PATHOGENIC VARIANT CARRIERS
Jul 9, 2026, 19:54 PM